Leptin and the sympathetic connection of fat to bone

Osteoporosis International

Volumn 19, Issue 7, 2008, Pages 905-912

  Hamrick, M W ^a   Ferrari, S L ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Adipogenesis; Beta adrenergic receptor; Body weight; Bone mass; Leptin receptor

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; FAT; LEPTIN; LEPTIN RECEPTOR; PROPRANOLOL; RECOMBINANT LEPTIN;

BODY COMPOSITION; BONE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE TISSUE; BONE TURNOVER; DNA POLYMORPHISM; DRUG EFFECT; HUMAN; HYPOTHALAMUS; LEAN BODY WEIGHT; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYMPATHETIC FUNCTION; WEIGHT GAIN;

ADIPOGENESIS; ANIMALS; BODY WEIGHT; BONE DENSITY; BONE DEVELOPMENT; HUMANS; LEPTIN; MICE; OBESITY; POLYMORPHISM, GENETIC; RECEPTORS, LEPTIN; RECEPTORS, NEUROPEPTIDE Y;

EID: 44449087465     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0487-9     Document Type: Review

References (95)

1. Rauch F, Bailey D, Baxter-Jones A et al (2004) The 'muscle-bone unit' during the pubertal growth spurt. Bone 34:771-775
2. Greenlund LJ, Nair KS (2003) Sarcopenia-consequences, mechanisms, and potential therapies. Mech Ageing Dev 124:287-299
3. Huang R, Rubin C, McLeod K (1999) Changes in postural muscle dynamics as a function of age. J Gerontol A Biol Sci Med Sci 54:B352-357
4. Eisman J (2001) Good, good, good.good vibrations: the best option for better bones? Lancet 358:1924-1925
5. Schoenau E (2005) From mechanostat theory to development of the "Functional Muscle-Bone Unit". J Musculoskelet Neuronal Interact 5:232-238
6. Qin Y, Lam H, Orzechowski L, Xia Y (2005) Bone fluid flow induced by skeletal muscle dynamics and its role in bone adaptation. J Bone Miner Res 20(Suppl 1):F185
7. Galvard H, Elmstahl S, Elmstahl B et al (1996) Differences in body composition between female geriatric hip fracture patients and healthy controls: body fat is more important as an explanatory factor for the fracture than body weight and lean body mass. Aging Clin Exp Res 8:282-286
8. Reid I, Ames R, Evans M, Sharpe S, Gamble G, France J, Lim T, Cundy T (1992) Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab 75:45-51
9. Fogelholm G, Sievänen H, Kukkonen-Harjula T, Pasanen M (2001) Bone mineral density during reduction, maintenance, and regain of body weight in premenopausal, obese women. Osteoporos Int 12:199-206
10. Grodin J, Siiteri P, MacDonald P (1973) Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36:207-214
11. Reid I (2002) Relationships among body mass, its components, and bone. Bone 13:547-555
12. Berner H, Lyngstadaas S, Spahr A et al (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35:842-849
13. Jürimäe J, Jürimäe T (2007) Adiponectin is a predictor of bone mineral density in middle- aged premenopausal women. Osteoporos Int [Mar 30 ePub ahead of print]
14. Reid I, Cornish J, Baldock P (2006) Nutrition-related peptides and bone homeostasis. J Bone Miner Res 21:495-500
15. Hamrick MW (2007) Invited perspective: leptin and bone-a consensus emerging? BoneKey-Osteovision 4:99-107
16. Flier J (1998) What's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab 83:1407-1413
17. Soyka L, Grinspoon S, Levitsky L et al (1999) The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 84:4489-4496
18. Mantzoros CS (2000) Role of leptin in reproduction. Ann N Y Acad Sci 900:174-183
19. Frisch R, Revelle R (1970) Height and weight at menarche and a hypothesis of critical body weights and adolescent events. Science 169:397-399
20. Matkovic V, Ilich J, Skugor M et al (1997) Leptin is inversely related to age at menarche in human females. J Clin Endocrinol Metab 82:3239-3245
21. Rosenthal D, Mayo-Smith W, Hayes C et al (1989) Age and bone mass in premenopausal women. J Bone Miner Res 4:533-538
22. Bonjour J-P, Chevalley T (2007) Pubertal timing, peak bone mass and fragility fracture risk. BoneKEy-Osteovision 4:30-48
23. Clark EM, Ness AR, Tobias JH (2006) Adipose tissue stimulates bone growth in prepubertal children. J Clin Endocrinol Metab 91:2534-2541
24. Chehab F, Lim ME, Lu R (1996) Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 12:318-320
25. Carro E, Senaris R, Considine R, Casanueva F, Dieguez C (1997) Regulation of in vivo growth hormone secretion by leptin. Endocrinology 138:2203-2206
26. Gat-Yablonski G, Ben-Ari T, Shaif B et al (2004) Leptin reverses the inhibitory effect of caloric restriction on longitudinal growth. Endocrinology 145:343-350
27. Welt C, Chan J, Bullen J et al (2004) Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 351:987-997
28. Yamauchi M, Sugimoto T, Yamaguchi T, Nakaoka D, Kanzawa M, Yano S, Ozuru R, Sugishita T, Chihara K (2001) Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol 55:341-347
29. Thomas T, Burguera B, Melton L et al (2001) Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 29:114-120
30. Blain H, Vuillemin A, Guillemin F et al (2002) Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab 87:1030-1035
31. Weiss L, Barrett-Connor E, von Muhlen D, Clark P (2006) Leptin predicts BMD and one resorption in older women but not older men: the Rancho-Bernardo study. J Bone Miner Res 21:758-764
32. Lorentzon M, Landin K, Mellström D, Ohlsson C (2006) Leptin is a negative independent predictor of areal BMD and cortical bone size in young adult Swedish men. J Bone Miner Res 21:1871-1878
33. Martin A, David V, Malaval L et al (2007) Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor-1 pathway. Endocrinology 148:3419-3425
34. Considine RV, Considine EL, Williams CJ et al (1996) The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations. Diabetes 45:992-994
35. Matsuoka N, Ogawa Y, Hosoda K et al (1997) Human leptin receptor gene in obese Japanese subjects: evidence against either obesity-causing mutations or association of sequence variants with obesity. Diabetologia 40:1204-1210
36. Chung WK, Power-Kehoe L, Chua M et al (1997) Exonic and intronic sequence variation in the human leptin receptor gene (LEPR). Diabetes 46:1509-1511
37. Quinton ND, Lee AJ, Ross RJ, Eastell R, Blakemore AI (2001) A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum Genet 108:233-236
38. Chagnon YC, Wilmore JH, Borecki IB et al (2000) Associations between the leptin receptor gene and adiposity in middle-aged Caucasian males from the HERITAGE family study. J Clin Endocrinol Metab 85:29-34
39. Fairbrother UL, Tanko LB, Walley AJ et al (2007) Leptin receptor genotype at Gln223Arg is associated with body composition, BMD, and vertebral fracture in postmenopausal Danish women. J Bone Miner Res 22:544-550
40. Koh JM, Kim DJ, Hong JS et al (2002) Estrogen receptor alpha gene polymorphisms Pvu II and Xba I influence association between leptin receptor gene polymorphism (Gln223Arg) and bone mineral density in young men. Eur J Endocrinol 147:777-783
41. Crabbe P, Goemaere S, Zmierczak H et al (2006) Are serum leptin and the Gln223Arg polymorphism of the leptin receptor determinants of bone homeostasis in elderly men? Eur J Endocrinol 154:707-714
42. Richert L, Chevalley T, Manen D et al (2007) Bone mass in prepubertal boys is associated with a Gln223Arg amino acid substitution in the leptin receptor. J Clin Endocrinol Metab
43. Thomas T (2004) The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 4:295-300
44. Holloway WR, Collier FM, Aitken CJ et al (2002) Leptin inhibits osteoclast generation. J Bone Miner Res 17:200-209
45. Burguera B, Hofbauer L, Thomas T et al (2001) Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 142:3546-3553
46. Thomas T, Gori F, Khosla S et al (1999) Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140:1630-1638
47. Hess R, Pino A, Rios S, Fernandez M, Rodriguez J (2004) High affinity leptin receptors are present in human mesenchymal stem cells (MSCs) derived from control and osteoporotic donors. J Cellular Biochem 94:50-57
48. Laharrague P, Larrouy D, Fontanilles AM (1998) High expression of leptin by human bone marrow adipocytes in primary culture. FASEB J 12:747-752
49. Kim G, Hong J, Kim S et al (2003) Leptin induces apoptosis via ERK/cPLA2/Cytochrome c pathway in human bone marrow stromal cells. J Biol Chem 278:21920-21929
50. Hamrick M, Della-Fera MA, Hartzell D, Choi Y-H, Baile CA (2007) Intrahypothalamic injections of leptin increase adipocyte apoptosis in peripheral fat pad and in bone marrow. Cell Tissue Res 327:133-141
51. Meunier P, Aaron J, Edouard C, Vignon G (1971) Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. Clin Orthop Rel Res 80:147-154
52. Kajkenova O, Lecka-Czernik F, Gubrij I et al (1997) Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res 12:1772-1779
53. Justesen J, Stenderup K, Ebbesen E et al (2001) Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2:165-171
54. Verma S, Rajaratnam J, Denton J et al (2002) Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 55:693-698
55. Lazarenko O, Rzonca S, Hogue W et al (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669-2680
56. Schwartz A, Sellmeyer D, Vittinghoff D et al (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-3354
57. Elmquist JK, Maratos-Flier E, Saper CB et al (1998) Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1:445-450
58. Ducy P, Amling M, Takeda S, Priemel M, Schilling A, Beil F, Shen J, Vinson C, Rueger J, Karsenty G (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197-207
59. Elefteriou F, Ahn JD, Takeda S et al (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514-520
60. Hamrick MW, Pennington C, Newton D, Xie D, Isales C (2004) Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34:376-383
61. Baldock PA, Allison S, McDonald MM et al (2006) Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res 21:1600-1607
62. Kellenberger S, Muller K, Richener H, Bilbe G (1998) Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating beta2-adrenergic receptors. Bone 22:471-478
63. Moore RE, Smith CK, II, Bailey CS, Voelkel EF, Tashjian AH, Jr (1993) Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner 23:301-315
64. Suzuki A, Guicheux J, Palmer G et al (2002) Evidence for a role of p38 MAP kinase in expression of alkaline phosphatase during osteoblastic cell differentiation. Bone 30:91-98
65. Suzuki A, Palmer G, Bonjour JP, Caverzasio J (1998) Catecholamines stimulate the proliferation and alkaline phosphatase activity of MC3T3-E1 osteoblast-like cells. Bone 23:197-203
66. Takeda S, Elefteriou F, Levasseur R et al (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317
67. Togari A, Arai M, Mizutani S, Mizutani S, Koshihara Y, Nagatsu T (1997) Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci Lett 233:125-128
68. Arai M, Nagasawa T, Koshihara Y, Yamamoto S, Togari A (2003) Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim Biophys Acta 1640:137-142
69. Togari A, Mogi M, Arai M, Yamamoto S, Koshihara Y (2000) Expression of mRNA for axon guidance molecules, such as semaphorin-III, netrins and neurotrophins, in human osteoblasts and osteoclasts. Brain Res 878:204-209
70. Takeuchi T, Tsuboi T, Arai M, Togari A (2001) Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem Pharmacol 61:579-586
71. Glatt V, Canalis E, Stadmeyer L, M Bouxsein (2007) Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner Res 22:1197-1207
72. Cao J, Venton L, Sakata T, Halloran BP (2003) Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res 18:270-277
73. Pierroz D, Muzzin P, Glatt V et al (2004) β1β2-adrenergic receptor ko mice have decreased total body and cortical bone mass despite increased trabecular bone number. J Bone Miner Res 19(supp 1):1121
74. Fu L, Patel M, Bradley A et al (2005) The molecular clock mediates leptin-regulated bone formation. Cell 122:803-815
75. Turek F, Joshu C, Kohsaka A et al (2005) Obesity and metabolic syndrome in circadian Clock mutant mice. Science 308:1043-1045
76. Gomez-Abellan P, Hernandez-Morante, Lujan J et al (2007) Clock genes are implicated in the human metabolic syndrome. Int J Obesity 1-8
77. Pierroz D, Bouxsein M, Cavat F et al (2006) Synergistic effects of adrenergic blockade and intermittent parathyroid hormone on bone in ovariectomized mice. Bone 39:260-267
78. Bonnet N, Beaupied H, Vico L et al (2007) Combined effects of exercise and propranolol on bone tissue in ovariectomized rats. J Bone Miner Res 22:578-588
79. Bonnet N, Laroche N, Vico L et al (2006) Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther 318:1118-1127
80. Pierroz D, Bouxsein ML, Muzzin P et al (2005) Bone loss following ovariectomy is maintained in absence of adrenergic receptor ß1 and ß2 signaling. J Bone Miner Res 20(Suppl.1):S277
81. Dhillon H, Glatt V, Ferrari S, Bouxsein ML (2004) β-Adrenergic receptor KO mice have increased bone mass and strength but are not protected from ovariectomy-induced bone loss. J Bone Miner Res 19(Suppl.1):S32
82. Marenzana M, De Souza RL, Chenu C (2007) Blockade of beta-adrenergic signaling does not influence the bone mechano-adaptive response in mice. Bone 41:206-215
83. Zeman RJ, Hirschman A, Hirschman ML et al (1991) Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated hindlimbs. Am J Physiol 261(2 Pt 1):E285-E289
84. Baker JG, Hall IP, Hill SJ (2003) Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64:1357-1369
85. Pierroz D, Baldock PA, Bouxsein ML, Ferrari S (2006) Low cortical bone mass in mice lacking beta 1 and beta 2 adrenergic receptors is associated with low bone formation and circulating IGF-1. J Bone Min Res 21(Suppl. 1):S26
86. Levasseur R, Dargent-Molina P, Sabatier JP et al (2005) Beta-blocker use, bone mineral density, and fracture risk in older women: results from the Epidemiologie de l'Osteoporose prospective study. J Am Geriatr Soc 53:550-552
87. Pasco JA, Henry MJ, Sanders KM et al (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. J Bone Miner Res 19:19-24
88. Reid IR, Gamble GD, Grey AB, et al (2005) Beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20:613-618
89. Reid IR, Lucas J, Wattie D et al (2005) Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 90:5212-5216
90. Rejnmark L, Vestergaard P, Kassem M et al (2004) Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 75:365-372
91. Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24:581-589
92. Schlienger RG, Kraenzlin ME, Jick SS et al (2004) Use of beta-blockers and risk fractures. JAMA 292:1326-1332
93. Khosla S (2002) Leptin-central or peripheral to the regulation of bone metabolism? Endocrinology 143:4161-4164
94. Hamrick MW (2004) Leptin, bone mass, & the thrifty phenotype. J Bone Miner Res 19:1607-1611
95. Baldock P, Allison S, McDonald M et al (2006) Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res 21:1600-1607